Shanghai GenePharma Co., Ltd. signed a non-exclusive worldwide license to use the Kreutzer-Limmer siRNA patents belonging to Alnylam Pharmaceuticals (NASDAQ:ALNY). The license, which is the first transaction Alnylam has signed with a China biotech, covers the right to manufacture and provide RNAi research products and services. GenePharma will manufacture RNAi reagent products for research use in China and worldwide.
The Kreutzer-Limmer patent family involves aspects of the structure and uses of RNAi products, including their use to mediate RNAi in mammalian cells.
Alnylam has entered 16 license agreements for the Kreutzer-Limmer patents with research product suppliers.
Founded in 2003, Shanghai GenePharma specializes in developing and manufacturing RNA synthesis monomers, modified RNA monomers, siRNA oligos, miRNA oligos, etc. It is currently expanding into large-scale siRNA synthesis. Shanghai GenePharma also develops new chemically modified siRNA synthesis technologies, miRNA purification, detection technologies, and it has begun to supply comprehensive RNAi-related services to academic and industrial customers.